Imaging probes targeting matrix metalloproteinases.

PubWeight™: 0.85‹?›

🔗 View Article (PMID 17105415)

Published in Cancer Biother Radiopharm on October 01, 2006

Authors

Christophe Van de Wiele1, Ruth Oltenfreiter

Author Affiliations

1: Department of Nuclear Medicine, University Hospital Ghent, Ghent, Belgium. christophe.vandewiele@ugent.be

Articles by these authors

Intra-arterial treatment with ⁹⁰Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. Eur J Nucl Med Mol Imaging (2011) 1.50

Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity. J Mol Biol (2007) 1.13

Probes for non-invasive matrix metalloproteinase-targeted imaging with PET and SPECT. Curr Pharm Des (2013) 0.91

Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging. Eur J Nucl Med Mol Imaging (2002) 0.89

In vivo imaging of apoptosis in oncology: an update. Mol Imaging (2011) 0.88

In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker. Nucl Med Biol (2005) 0.85

In vitro and in vivo evaluation of [99mTc]-labeled tricarbonyl His-annexin A5 as an imaging agent for the detection of phosphatidylserine-expressing cells. Nucl Med Biol (2010) 0.83

Membrane type 1 matrix metalloproteinase detection in tumors, using the iodinated endogenous [123I]-tissue inhibitor 2 of metalloproteinases as imaging agent. Cancer Biother Radiopharm (2010) 0.77

In vivo evaluation of [123I]-4-iodo-N-(4-(4-(2-methoxyphenyl)-piperazin-1-yl)butyl)-benzamide: a potential sigma receptor ligand for SPECT studies. Nucl Med Biol (2005) 0.77

Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factor. Nucl Med Commun (2005) 0.75

Synthesis and assessment of [11C]acetylhomotaurine as an imaging agent for the study of the pharmacodynamic properties of acamprosate by positron emission tomography. Nucl Med Biol (2004) 0.75

In vivo evaluation of [(123)I]-3-(4-iodobenzyl)-1,2,3,4-tetrahydro-8-hydroxychromeno[3,4-c]pyridin-5-one: a presumed dopamine D4 receptor ligand for SPECT studies. Nucl Med Biol (2005) 0.75